About Us

Strive to make high quality products of stroke treatment and prevention

Company Introduction

Shanghai HeartCare Medical Technology Co., Ltd. (stock code: 06609.HK) was established in 2016. The company is committed to improving the accessibility of innovative medical technology and protecting life and health. In the past six years, HeartCare Medical has pioneered the creation of the first one-stop solution for stroke treatment and prevention in China in the field of neurological intervention. It owns the whole product pipeline from acute ischemic stroke and neurovascular stenosis treatment, ischemic stroke prevention and hemorrhagic stroke treatment to interventional access equipment, and has applied for more than 200 patents, and its sales channels cover all provinces nationalwide other than Hong Kong, Macao and Taiwan.

Based on the existing leading advantages, HeartCare Medical will continue to focus on popularizing new medical techniques, focus on the unmet needs of clinicians and patients in China, and operate a number of new business segments including nerve intervention, Cardiac therapy, pulmonary intervention and computer-aided technology, expecting that in these medical fields with great potential, Continuously introduce innovative interventional instruments that define new surgical methods to reduce the mortality of major diseases and improve the prognosis of patients.

6 years

COMPANY HISTORY

15

COMMERCIALIZED PRODUCTS

200 +

PATENTS FILED

10 +

SOLUTION

Development path

2016.6

We were established as a limited liability company in the PRC under the name of “Shanghai Care Medical Technology Corporation Limited ”.

2019.12

We obtained NMPA registration certificates for our ExtraFlex™ distal access catheter and SupSelek™ microcatheter.

2020.8

We obtained NMPA registration certificate for our Captor™ thrombectomy device, being the first domestic multi-markers thrombectomy stent retriever in the PRC.


2020.12

We commercialized our Captor™ thrombectomy device as the first domestic multi-markers thrombectomy stent retriever in the PRC.

2020.12

We obtained NMPA registration certificate for our Fullblock™ balloon guiding catheter.

2021.1

We completed the clinical trial for our LAA occluder.

2021.5

Neuro Balloon Dilatation Catheter (Openvas) approved by NMPA

2021.6

PTA Balloon Dilatation catheter (Thruvas)approved by NMPA

2021.6

Entered thelife Blue Bay Park of LINGANG specialareaand opened production base

2021.7

Aspiration Pump(QUIKVAC)approved by NMPA

2021.8

Listing on the main board of the Hong Kong Stock Exchange

2021.12

Embolic Protection System(FullTrap)approved by NMPA

2021.12

Neuro Micro Gudie Wire (EasyWire)approved by NMPA

2022.2

Micro Catheter(SUPSELEK)approved by FDA (510k)

2022.2

Vascular Closure Device approved by NMPA

2022.2

Invest in Shanghai IasoCardiac Medical Technology Co., Ltd.


2022.3

Embolization coil system(Sealsac)approved by NMPA


2022.4

Aspiration Catheter(FlowPlus)approved by NMPA

2022.4

Support Catheter(SPTFLEX)approved by NMPA

2022.4

Left Atrial Appendage Occluder System (Laager)Laager approved by NMPA

DIRECTORS, SUPERVISORS AND SENIOR MANAGEMENT

The board consists of 8 directors, which include 3 executive directors, 2 non-executive directors and 3 independent executive directors.

Name Position
Mr. WANG Guohui Chairman of the Board,executive Director and chief executive officer
Ms. ZHANG Kun Executive Director and deputy general manager
Mr. WEI Jiawei Executive Director and deputy general manager
Mr. DING Kui Non-executive Director
Mr. GUO Shaomu Independent Nonexecutive Director
Mr. GUO Shaomu Independent Nonexecutive Director
Mr. GUO Shaomu Independent Nonexecutive Director

 

SENIOR MANAGEMENT:

Name Position
Mr. WANG Guohui Chairman of the Board,executive Director and chief executive officer
Ms. ZHANG Kun Executive Director and deputy general manager
Mr. LI Zhigang Deputy general manager
Mr. WEI Jiawei Deputy general manager
Mr. ZHANG Han Chief Financial Officer

Awards and Qualification

2022

"The most popular new stock company" of the 6th golden Hong Kong stock award ceremony

2021

"Annual most powerful IPO" in GuruClub Greater China Best listed Company


2021

Shanghai high tech enterprise


2021

Leading star of LinGang Park


2021

The third prize of China Medical Device Innovation and entrepreneurship competition


2021

Partner of "china alliance of neurointerventional intervention andtransformation "

2021

Award theindustry model ofInternational quality Festival 2021


2021

China forum of cerebrovascular disease


2020

Top 100 medical devices companies ofChina future healthcare rankings


2020

Top 10 high value consumables list of medical and health enterprises with the most investment value


2020

Award the Innovation Star of the 4th Health Investment Association


2020

The third prize of the 3th China Medical Device Innovation and Entrepreneurship Competition


2020

The first prize of 3th China Medical Device Innovation and Entrepreneurship Competition


2020

"Start business in Shanghai" international innovation and Entrepreneurship Competition


2020

Award the Responsibility Brand of the 10th public welfare Festival


2020

The best innovative medical device enterpriseof medical and health investment excellence list


2019

The director unit of Shanghai Biomedical Industry Association


2019

The second prize of China Medical Device Innovation and Entrepreneurship Competition


2019

The new power enterprisInsight of Zhangjiang


2019

Top 5 of companies in mini-invasive therapies of china future healthcare rankings


Our Vision